Valerion Therapeutics, formerly 4s3 Bioscience, is developing therapies for orphan genetic muscle diseases utilizing a novel antibody-based targeting system capable of enhanced intracellular delivery.   Demonstrated pre-clinical in vivo data with the company’s two lead product candidates validates the potential of Valerion’s delivery platform for delivering muscle-protein fusions and treating multiple indications in the fields of muscular dystrophies and enzyme-deficiency disorders.

Learn more at valerion.com